dry eye – Web Xpress http://web-xpress.com/ Mon, 18 Apr 2022 12:18:11 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://web-xpress.com/wp-content/uploads/2021/10/icon-9-150x150.png dry eye – Web Xpress http://web-xpress.com/ 32 32 Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer | Nation/World https://web-xpress.com/aerie-pharmaceuticals-appoints-peter-lang-as-chief-financial-officer-nation-world/ Fri, 18 Mar 2022 11:02:07 +0000 https://web-xpress.com/aerie-pharmaceuticals-appoints-peter-lang-as-chief-financial-officer-nation-world/ DURHAM, NC–(BUSINESS WIRE)–March 18, 2022– Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of advanced ophthalmic therapies, today announced that Peter F. Lang will join the company as Chief Financial Officer, effective effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals […]]]>

DURHAM, NC–(BUSINESS WIRE)–March 18, 2022–

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of advanced ophthalmic therapies, today announced that Peter F. Lang will join the company as Chief Financial Officer, effective effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of Aerie’s Executive Committee.

“I am delighted to welcome Peter to our leadership team,” said Raj Kannan, President and CEO. “His extensive experience in investment banking and helping life science companies raise, manage and deploy capital, including business development and M&A transactions, will be important in maximizing shareholder value. I am confident that Peter will provide strong leadership and be a great addition to the Aerie team.

Peter Lang added: “I have spent my career working with life sciences companies to help them optimize their growth objectives, funding strategy, capital structure and return on capital, so that they can successfully advance their business plan and meet the needs of patients. I am very excited to join Aerie at this exciting time, with a growing glaucoma business franchise, a strong and innovative pipeline and an experienced team. I look forward to working with Raj and the management team to sustainably grow the business and bring significant value to patients, clinicians and investors.

Peter comes to Aerie with over 25 years of experience providing financial, strategic and operational solutions, with deep expertise in healthcare and a particular focus on the biopharmaceutical sector. He has held senior positions in recognized global and specialty investment banks. Additionally, he has extensive experience working with management teams and boards to optimize business growth plans, capital structures and return on capital. During his career, he has helped raise approximately $105 billion in financing and growth capital and advised on more than 40 M&A and business development transactions totaling over $25 billion in value.

Peter joins Aerie from Ridge Advisory, LLC, where he was Managing Director and Partner. Prior to working at Ridge Advisory, Peter held various senior positions in the healthcare investment banking divisions of well-regarded firms including HSBC, Bank of America Merrill Lynch, UBS Investment Bank and Leerink Partners. Peter holds an MBA from the University of Chicago, Booth School of Business, with Top honors. Peter graduated with a double degree, Magna Cum Laude, from the Wharton School of Business and the School of Arts & Sciences at the University of Pennsylvania.

About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with ocular diseases and conditions, including open-angle glaucoma, dry eye, macular edema diabetic (OMD) and wet age. associated macular degeneration (wet AMD). Aerie’s first innovative product, Rhopressa ® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drops approved by the United States Food and Drug Administration (FDA) for the reduction of intraocular pressure ( elevated IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal whorls , pain at the instillation site and conjunctival hemorrhage. More information about Rhopressa ®, including the product label, is available at www.rhopressa.com. Aerie’s second new product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan ®, the most common adverse reactions were conjunctival hyperemia, corneal whorls, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan ®, including the product label, is available at www.rocklatan.com. For more information about Aerie Pharmaceuticals, visit www.aeriepharma.com.

Forward-looking statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in certain circumstances, use terms such as “predicted”, “believes”, “potential”, “propose”. , “”continues”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “could”, “will”, ” should”, “explore”, “pursue” or other words that convey uncertainty of future events or results to identify these forward-looking statements. The forward-looking statements in this release include statements about our intentions, beliefs, our current projections, outlook, analysis or expectations regarding, among other things, our business franchise and pipeline. By their nature, forward-looking statements involve risks and uncertainties as they relate to events, competitive dynamics , industry developments and other factors beyond our control, and are dependent on regulatory approvals and economic and environmental circumstances that may or may not occur in the future. longer or shorter than expected. We discuss many of these risks in more detail under the heading “Risk Factors” in our quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements we make in this press release speak only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220318005084/en/

CONTACT: Media:

Caroline McAuliffe

cmcauliffe@aeriepharma.com

(949) 526-8733Investors:

LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.

Hans Vitzthum

hans@lifesciaadvisors.com

(617) 430-7578

KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA

INDUSTRY KEYWORD: PHARMACEUTICAL OPTICAL HEALTH OTHER HEALTH

SOURCE: Aerie Pharmaceuticals, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 03/18/2022 07:00 / DISK: 03/18/2022 07:02

http://www.businesswire.com/news/home/20220318005084/en

]]>
Blurred vision after surgery: causes, recovery, etc. https://web-xpress.com/blurred-vision-after-surgery-causes-recovery-etc/ Mon, 14 Mar 2022 23:53:08 +0000 https://web-xpress.com/blurred-vision-after-surgery-causes-recovery-etc/ Blurred vision can be a common side effect of eye surgeries. In fact, any operation on or around your eyes can cause temporary vision changes, including blurred vision. Other potential vision problems depend on the type of surgery you had, as well as the type of anesthesia used. Cataract surgery Cataracts are caused by proteins […]]]>

Blurred vision can be a common side effect of eye surgeries. In fact, any operation on or around your eyes can cause temporary vision changes, including blurred vision.

Other potential vision problems depend on the type of surgery you had, as well as the type of anesthesia used.

Cataract surgery

Cataracts are caused by proteins that can change or break down inside your eye. When this happens, the proteins can clump together and form whitish, yellow or brown clumps that cover the natural lens of your eye. These clumps impair your vision by making things blurry or hazy.

Cataracts take years to develop and are more common in older people.

Cataract surgery usually takes place in an operating room. It is generally a quick and safe procedure with a high success rate.

You will usually receive local anesthesia during cataract surgery. This numbs the nerves around your eye so you won’t feel any pain or discomfort.

During the procedure, a doctor will remove the cloudy natural lens from your eye. They will replace it with a transparent artificial lens implant called an intraocular lens.

Blurred vision is common immediately after cataract surgery. It usually disappears in 2 to 3 days. In some cases, however, it may take a week or more for the blurred vision to go away.

In addition to blurry vision, it is not uncommon to experience some sensitivity to light immediately after surgery. More serious complications are rare.

Vitrectomy

A vitrectomy is eye surgery that removes the vitreous humor from your eye. This is a gel-like substance that fills the back chamber of your eye.

You may need to remove the vitreous if you have problems with your retina. The retina is a collection of cells at the back of your eye that sends visual signals to your brain to help it interpret images.

A vitrectomy is done in an operating room. You will usually receive a longer-acting local anesthetic around your eye.

After a surgeon removes the vitreous, they replace it with a saline solution or bubble. Over time, your body will produce more natural fluid, refilling the eye socket.

If there are no complications, most people leave the hospital within hours of having a vitrectomy.

Blurred vision after vitrectomy is possible and can last 2-3 days. However, blurred vision may last longer if you have both vitrectomy and retinal surgery.

After the procedure, some people also experience a gritty or scratchy sensation in their eyes. Both issues should disappear within a few days. The surgeon may prescribe eye drops to help with healing.

Eyelid surgery

Blepharoplasty is an eyelid surgery that corrects droopy eyelids.

Typically, you will receive local anesthesia instead of general anesthesia. This means that recovery after eyelid surgery is relatively quick.

During this procedure, a surgeon will remove fat, muscle, or excess skin from your eyelid. They will then stitch up the eyelid to prevent it from falling.

You will likely go home a few hours after surgery. However, short-term side effects like blurred vision and light sensitivity are possible. These usually disappear within a few days.

LASIK or PRK surgery

Laser-assisted in situ keratomileusis (LASIK) is a common eye surgery used to treat nearsightedness, farsightedness, and astigmatism.

As with many eye surgeries, local anesthesia is commonly used and you can go home within hours.

During the operation, a surgeon will use lasers and small blades to reshape the cornea of ​​your eye. This will allow your eyes to properly focus the light and should result in better vision. It generally eliminates the need for corrective lenses like glasses or contacts.

Some people may experience a gritty or sandy texture in their eyes after surgery. Dry eye, which can cause blurred vision, is also quite common after LASIK surgery.

Blurry vision can last for several days, but usually goes away on its own. You will need antibiotic and steroid eye drops for proper healing. Eye drops can also help lubricate your eyes as they heal.

Photorefractive keratectomy (PRK) laser surgery is an older procedure similar to LASIK. It is also used to help correct vision by reshaping corneal tissue.

With PRK, a surgeon will completely remove the top layer of corneal tissue. They will then use a laser to reshape the irregular corneal tissue.

Recovery is similar to LASIK, but blurred vision may last longer as the surface of the eye continues to heal.

Retinal detachment surgery

If your retina detaches from the tissues of your eye, you may experience immediate vision problems, including:

  • Blurred vision
  • partial vision loss
  • sudden flashes of light in your field of vision

Retinal detachment is a medical emergency. It must be treated quickly to help reduce the risk of permanent vision loss.

Surgery can repair a detached retina. Most often, this surgery can be performed under local anesthesia injected around the eye.

Recovery, however, may take longer. You will likely experience short-term side effects like watery eyes and blurred vision for several days after surgery. Regular vision may not return for 2 to 4 weeks.

Some people may need additional surgeries to completely correct vision problems after retinal detachment.

Cornea transplant

Corneal transplantation, or keratoplasty, is necessary if the cornea of ​​your eye is damaged or diseased. During this operation, a surgeon will replace the cornea with donated corneal tissue. Once healed, the new tissue should restore vision.

Recovering from a corneal transplant can take several months. Most short-term side effects, including blurred vision, can last a few weeks or longer.

A doctor may ask you to wear a face shield or eye protection for several days to help the tissues heal. Once removed, side effects like blurred vision may occur as your eyes readjust.

Your doctor will likely prescribe medicated eye drops to help reduce side effects. Glasses and contact lenses may be needed for long-term clear vision.

]]>
Sodium Hyaluronate Eye Drops Market Size, Competitor Strategy, Regional Analysis & Industry Growth By Forecast To 2028 – The Bollywood Ticket https://web-xpress.com/sodium-hyaluronate-eye-drops-market-size-competitor-strategy-regional-analysis-industry-growth-by-forecast-to-2028-the-bollywood-ticket/ Sun, 13 Mar 2022 14:39:39 +0000 https://web-xpress.com/sodium-hyaluronate-eye-drops-market-size-competitor-strategy-regional-analysis-industry-growth-by-forecast-to-2028-the-bollywood-ticket/ Reports and Data has released a new report on Sodium Hyaluronate Eye Drops Market which offers a comprehensive overview of the market and helps investors and users understand market dynamics and make investment plans accordingly. The report provides details about market revenue growth, market size, drivers, restraints, limitations, growth opportunities, and top companies. The report […]]]>

Reports and Data has released a new report on Sodium Hyaluronate Eye Drops Market which offers a comprehensive overview of the market and helps investors and users understand market dynamics and make investment plans accordingly. The report provides details about market revenue growth, market size, drivers, restraints, limitations, growth opportunities, and top companies. The report also focuses on manufacturing and production and recent collaborations of market players. The report is formulated from extensive primary and secondary research and verified by industry experts and professionals. Data is well represented by charts, graphs, tables, figures and other pictorial presentations.

Get a sample report @ https://www.reportsanddata.com/sample-enquiry-form/428

Market Overview:

The global sodium hyaluronate eye drops market has grown significantly over the past few years and is expected to witness rapid growth during the forecast period of 2021 to 2028. The pharmaceutical and healthcare industry is rapidly changing with technological innovations, increased health expenditure and improved health facilities. and systems. Many hospitals, outpatient surgical centers and clinics around the world are adopting state-of-the-art devices and equipment. The revenue growth of the global sodium hyaluronate eye drops market is largely driven by factors such as rising prevalence of chronic diseases, rapid advancements in healthcare and medical sectors, high adoption of the latest tools and techniques and the growth of funds by several public and private sectors. In addition, increasing attention to drug development, increasing demand for precision medicine, high adoption of home care settings and point-of-care diagnostics, increasing investment in research activities and development are expected to drive the revenue growth of the global market over the forecast period.

The ongoing pandemic is significantly changing the dynamics of the pharmaceutical and healthcare sector. Various countries are facing challenges such as shortage of medicines, vaccines, health devices in hospitals. This is expected to open up lucrative growth opportunities for market players in the coming years.

Key Companies Featured in the Report:

  • Alcon
  • Altacor
  • Bausch & Lomb
  • Bayer, Inc.
  • Cigna
  • Bright Eyes
  • Johnson & Johnson
  • Novax Pharma
  • optrex
  • Refresh
  • Ritual Aid
  • Healthn
  • Scope Ophthalmics Ltd.
  • Similasan Company
  • Staples
  • Systane
  • United Laboratories
  • Thea Pharmaceuticals
  • URSAPHARM Arzneimittel GmbH
  • View
  • Viva Opti-free
  • Walgreens
  • Xiuzheng Pharmaceutical Group

To learn more about the report, visit @ https://www.reportsanddata.com/report-detail/sodium-hyaluronate-eye-drops-market

Competitive Landscape:

The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, licensing agreements, partnerships, mergers and acquisitions, collaborations and joint ventures to gain a strong foothold in the market.

Sodium Hyaluronate Eye Drops Market Segmentation:

Treatment Type Outlook (Revenue, USD Billion; 2018-2028)

  • dry eye disease
  • Sjogren’s Syndrome
  • Stevens Johnson Syndrome
  • Conjunctival
  • Corneal epithelial lesions

Distribution Channel Outlook (Revenue, USD Billion; 2018-2028)

Download the summary @ https://www.reportsanddata.com/download-summary-form/428

Regional outlook of the global sodium hyaluronate eye drops market

  • North America
  • Europe
    • K
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Argentina
    • Peru
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • EA
    • Rest of the Middle East and Africa

Request report customization @ https://www.reportsanddata.com/request-customization-form/428

Thanks for reading the research report on the Global Sodium Hyaluronate Eye Drops Market. Please contact us to learn more about the personalization feature and our team will suggest the report that best suits your needs.

About reports and data

Reports and Data is a market research and consulting firm that provides syndicated research reports, custom research reports and consulting services. Our solutions are uniquely focused on your goal to locate, target and analyze changes in consumer behavior across demographics, across industries, and help customers make smarter business decisions. We offer market intelligence research ensuring relevant and factual research across multiple sectors including healthcare, touchpoints, chemicals, commodities and energy. We are constantly updating our search offerings to ensure that our clients are aware of the latest trends existing in the market. Reports and Data has a strong base of experienced analysts from a variety of areas of expertise. Our industry experience and ability to develop a workable solution to any research problem gives our clients the ability to secure an edge over their respective competitors.

Contact us:

Jean W
Business Development Manager
Reports and data | The Web: www.reportsanddata.com
Direct line: +1-212-710-1370
E-mail: [email protected]
LinkedIn | Twitter | Blogs

]]>
Can diet have an impact on dry eyes? https://web-xpress.com/can-diet-have-an-impact-on-dry-eyes/ Tue, 08 Mar 2022 22:25:00 +0000 https://web-xpress.com/can-diet-have-an-impact-on-dry-eyes/ LANSING, Mich. (WILX) — Dry eye syndrome is a chronic condition in which your body doesn’t produce enough tears or the tears don’t lubricate your eyes enough. Related: Your health: New treatment relieves dry eyes It affects approximately 16 million people in the United States. New research suggests that your diet may improve symptoms. If […]]]>

LANSING, Mich. (WILX) — Dry eye syndrome is a chronic condition in which your body doesn’t produce enough tears or the tears don’t lubricate your eyes enough.

Related: Your health: New treatment relieves dry eyes

It affects approximately 16 million people in the United States. New research suggests that your diet may improve symptoms.

If your eyes are constantly irritated, itchy, red, or painful, you may have dry eye syndrome. Eye drops are a treatment option, but what you eat can also help or hurt your eyes.

“There’s definitely a correlation between a poor inflammatory diet and worsening dry eye, so things that are inflammatory. So dairy products are inflammatory. Meats are inflammatory. Eggs are inflammatory,” Dr. Rolando Toyos, from the Toyos clinic.

Toyos said people should avoid processed foods as much as possible. What should you eat? Omega-3 fatty acids – found in fish like trout, salmon, sardines and mackerel – can reduce inflammation and dry eye symptoms.

“If they don’t eat fish, we’ll start them on an omega-3 supplement,” Toyos said.

Vitamin C has also been shown to protect the eyes from pollution and improve tear production. It is abundant in broccoli, Brussels sprouts and citrus fruits.

Vitamin E – found in sunflower oil, almonds, pumpkin and spinach – helps protect the retina from injury and helps maintain the tear film layer in the eye.

Vitamin A, found in carrots, squash, and tuna, may also help reduce dry eye symptoms and improve tear quality. New research shows that the caffeine in beverages like coffee, black tea, and green tea can stimulate tear production.

Studies also show that vitamin D deficiency may be linked to worsening dry eye symptoms. The best way to get vitamin D is to spend 10-15 minutes in the sun every day.

Continued: Health Stories

Copyright 2022 WILX. All rights reserved.

Subscribe to our News newsletter 10 and get the latest local news and weather straight to your email every morning.

]]>
Awareness of Workplace Eye Wellness Month with Elizabeth Yeu, MD, Part 2 https://web-xpress.com/awareness-of-workplace-eye-wellness-month-with-elizabeth-yeu-md-part-2/ Tue, 08 Mar 2022 14:54:48 +0000 https://web-xpress.com/awareness-of-workplace-eye-wellness-month-with-elizabeth-yeu-md-part-2/ March 08, 2022 1 minute watch ADD A SUBJECT TO EMAIL ALERTS Receive an email when new articles are published on Please provide your email address to receive an email when new articles are published on . ” data-action=”subscribe”> Subscribe We have not been able to process your request. Please try […]]]>

March 08, 2022

1 minute watch


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

In part two of a five-part series, Elizabeth Yeu, MD, discusses distance learning, integrating technology into education, and how dry eye disease and symptomatology are affected.

]]>
Nicox Partner Fera Pharmaceuticals Obtains Orphan Drug https://web-xpress.com/nicox-partner-fera-pharmaceuticals-obtains-orphan-drug/ Wed, 02 Mar 2022 06:30:00 +0000 https://web-xpress.com/nicox-partner-fera-pharmaceuticals-obtains-orphan-drug/ March 2n/a2022 – release at 7:30 CET Sophia-Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), an international society of ophthalmology, and Fera Pharmaceuticals, a private US specialty pharmaceutical company, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to naproxcinod for the treatment of sickle cell disease, which affects […]]]>

March 2n/a2022 – release at 7:30 CET
Sophia-Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), an international society of ophthalmology, and Fera Pharmaceuticals, a private US specialty pharmaceutical company, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to naproxcinod for the treatment of sickle cell disease, which affects approximately 100,000 Americans. Naproxcinod is a nitric oxide (NO)-donating naproxen combining the cyclooxygenase (COX) inhibitory activity of naproxen with that of nitric oxide developed by Nicox and licensed exclusively to Fera in the United States. Nicox has tested naproxcinod in more than 2,700 patients with osteoarthritis, generating a significant body of clinical safety data that is available to support Fera’s development of naproxcinod and ultimately a New Drug Application submission for sickle cell disease.

“We congratulate Fera on obtaining Orphan Drug Designation for naproxcinod, which is a very important step to be able to develop this molecule as a potential treatment for sickle cell disease. Fera has already carried out pre-clinical development work on naproxcinod in sickle cell disease models, and the extensive clinical package already developed by Nicox positions the molecule, the first to go into clinical development by our company – for accelerated development.noted Michele Garufi, CEO and President of Nicox.

“Wwe are extremely happy this the FDA granted orphan drug status to naproxcinod because it now allows us to continue our development for sickle cell disease with the benefits that come with that designation. noted Frank DellaFera, founder and CEO of Fera Pharmaceuticals.

Aon orphan drug designation

The FDA’s Orphan Drug Designation program grants orphan drug status to drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare diseases that affect fewer than 200,000 people in the United States. Benefits of orphan drug designation in the United States include seven years of market exclusivity after FDA approval, waiver or partial payment of application fees, and tax credits for trial-related expenses. qualified clinics conducted after receipt of orphan designation.

Role of nitric oxide in sickle cell disease

Sickle cell disease is an inherited condition that affects red blood cells, with a faulty version of hemoglobin causing normally oval-shaped red blood cells to take on a sickle shape, leading to symptoms such as pain, frequent infections and anemia. Rupture of these cells into the bloodstream can lead to inflammation, reduced NO and subsequent thickening of the endothelial cell wall, as well as platelet activation. In this inflamed and reduced-volume environment, sickle-shaped red blood cells, leukocytes (white blood cells) and activated platelets aggregate to create a “vascular jam” (vaso-occlusion), leading to a painful vaso-occlusive crisis.

Nicox-Fera partnership

Naproxcinod, a cyclooxygenase inhibitor (CINOD) nitric oxide (NO) donating naproxen, is a nonsteroidal anti-inflammatory product candidate designed to release NO and naproxen, originally discovered and developed by Nicox. Nicox and Fera entered into an agreement in December 2015, amended in September 2018 and December 2020, which granted Fera exclusive rights to develop and commercialize naproxcinod for the US market. Nicox is eligible to potentially receive a one-time $40 million sales-based milestone if naproxcinod reaches $1 billion in annual sales (for any indication) in the United States as well as 7% royalties on future net sales of naproxcinod in the United States. Fera is responsible for all clinical development, manufacturing, regulatory, and commercialization activities in the United States.

Nicox retains all rights to naproxcinod outside of the United States, subject to payment of royalties to Fera, if intellectual property developed under the agreement is used outside of the United States

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve eye health. Nicox’s lead clinical development program is NCX 470, a novel nitric oxide-donating prostaglandin analog intended to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye. Nicox derives revenue from VYZULTA® in glaucoma, under exclusive worldwide license to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, under license in several geographies, including Eyevance Pharmaceuticals, LLC, in the United States and Ocumension Therapeutics in China and the majority of Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment C: Mid Caps; Ticker: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indices.

For more information about Nicox, its products or its pipeline, please visit: www.nicox.com.

The information contained in this document is subject to change without notice. This information includes forward-looking statements. These forward-looking statements are not guarantees of future performance. These statements are based on the current expectations or beliefs of the management of Nicox SA and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, advisors or agents, do not undertake and have no obligation to provide any updates or revise any forward-looking statements.

The risk factors likely to have a significant effect on Nicox’s business are presented in the 3rd chapter of ‘Universal registration document, annual financial report and management report 2020‘ filed with the French Financial Markets Authority (AMF) on March 1, 2021 and in the 2n/a chapter of the amendment to the “Universal Registration Document, annual financial report and management report 2020» filed with the AMF on December 9, 2021 which are available on the Nicox website (www.nicox.com).

]]>
GLAUKOS CORP MANAGEMENT REPORT AND ANALYSIS OF FINANCIAL POSITION AND RESULTS OF OPERATIONS (Form 10-K) https://web-xpress.com/glaukos-corp-management-report-and-analysis-of-financial-position-and-results-of-operations-form-10-k/ Mon, 28 Feb 2022 22:12:06 +0000 https://web-xpress.com/glaukos-corp-management-report-and-analysis-of-financial-position-and-results-of-operations-form-10-k/ You should read the following discussion and analysis of our financial condition and results of operations together with "Selected Financial Data" and our audited consolidated financial statements and related notes included in Items 6 and 8, respectively, of this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report […]]]>
You should read the following discussion and analysis of our financial condition
and results of operations together with "Selected Financial Data" and our
audited consolidated financial statements and related notes included in Items 6
and 8, respectively, of this Annual Report on Form 10-K. This discussion and
analysis and other parts of this Annual Report on Form 10-K contain
forward-looking statements that reflect our current plans, expectations,
estimates and beliefs that involve risks, uncertainties and assumptions, such as
statements regarding our plans, objectives, expectations, intentions and
projections. Our actual results and the timing of selected events may differ
materially from those discussed in these forward-looking statements. You should
carefully read Item 1A - "Risk Factors" included in this Annual Report on Form
10-K to gain an understanding of the important factors that could cause actual
results to differ materially from our forward-looking statements. Please also
see the section entitled "Special Note Regarding Forward-Looking Statements
and
Industry Data."

Overview
We are an ophthalmic medical technology and pharmaceutical company focused on
developing novel therapies for the treatment of glaucoma, corneal disorders, and
retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an
alternative to the traditional glaucoma treatment paradigm, launching our first
MIGS device commercially in 2012, and have since developed a portfolio of
technologically distinct and leverageable platforms to support ongoing
pharmaceutical and medical device innovations. Products or product candidates
for each of these platforms are designed to advance the standard of care through
better treatment options across the areas of glaucoma, corneal disorders such as
keratoconus, dry eye and refractive vision correction, and retinal diseases such
as neovascular age-related macular degeneration (AMD), diabetic macular edema
(DME), and retinal vein occlusion (RVO).

Impact of the COVID-19 pandemic and current economic environment


While the COVID-19 pandemic and subsequent economic slowdown materially impacted
the global demand for our products starting in March 2020, we began to see an
early recovery toward more normalized levels for cataract and keratoconus
procedures as early as May 2020, a trend that has generally continued, with
periodic volatility in certain geographies in which we operate, through December
31, 2021. Most recently the Omicron variant has led to a material increase in
diagnosed cases worldwide, creating new government restrictions in select
geographies and impacting elective procedures in hospital and ambulatory surgery
center sites. Additionally, the COVID-19 pandemic has led to widespread staffing
shortages, including in ambulatory surgery centers, which may also impact
elective procedures. These trends accelerated at the end of December 2021 and
continued through the date herein.

We continue to actively assess the impact of COVID-19 on our clinical trials and
other pipeline products. The closure of ophthalmic practices and deferral of
elective procedures beginning in the first quarter of 2020 in response to
COVID-19 disrupted new patient enrollment in our ongoing clinical trials. While
we cannot predict the full impact of COVID-19 on the timing of completion of our
clinical trials and the expected regulatory approvals for our pipeline products,
our disclosed targeted approval dates anticipate, to our best estimate, such
impact.

Additionally, some of our vendors are continuing to experience supply
challenges, both in the acquisition of raw materials as well as due to limited
headcount resources, and we have experienced higher costs for certain raw
materials. These challenges have led to delays and partial or unfulfilled
deliveries of certain components needed for the manufacture of our products, in
some cases requiring us to find second sources for materials. If these delays
and partial or unfulfilled deliveries persist, they could impact our ability to
ship some of our products to our customers, or bring some of our pipeline
products to market, in a timely manner. We believe that much of these supply
challenges stem from the ongoing obstacles presented by COVID-19.

In 2020, when COVID had its greatest financial impact to date, we sought to
preserve our cash position by instituting a number of cost saving initiatives,
including temporary reductions in discretionary spending and capital
expenditures. We temporarily deferred a significant portion of our planned 2020
capital expenditures, particularly those related to facilities expansion and
consolidation plans, which were reinstituted as state and local governments
began to

                                       37

  Table of Contents

authorize re-openings. Further, in June 2020, we issued an aggregate principal
amount of $287.5 million of 2.75% convertible notes due 2027 (the Convertible
Notes), the net proceeds of which will be used for working capital and general
corporate purposes. As of December 31, 2021, we had cash, cash equivalents,
short-term investments, and restricted cash of approximately $423.5 million,
compared to $413.9 million as of December 31, 2020.

The ultimate impact of the COVID-19 pandemic on our operations going forward is
unknown and will depend on future developments which are highly uncertain and
cannot be predicted with confidence, including the duration and severity of the
COVID-19 outbreak, the status of health and safety actions taken to contain its
spread, the severity and transmission rates of new variants of COVID-19 such as
the Delta and Omicron variants, the availability, distribution, and efficacy of
vaccines for COVID-19, any additional preventative and protective actions that
governments, or we, may take, any future surges of COVID-19 that may occur, the
dynamics associated with the rollout of the COVID-19 vaccines, and how quickly
and to what extent economic and operating conditions normalize within the
markets in which we operate. For additional information, see the section
titled Risks Related to Our Business within Item 1A. Risk Factors of this Annual
Report on Form 10-K.

Financial Overview

The most important financial indicators we use to evaluate our business are net sales, gross margin, operating expenses and cash.

                                                               December 31,      December 31,
                                                                   2021              2020
Net sales                                                     $      294,011    $      224,959
Gross margin                                                              77 %              59 %
Operating expenses                                            $     

260 256 $256,793
Cash, cash equivalents, short-term investments and restricted cash

                                               $      

423 467 $413,934

Please see Results of Operations and Liquidity and Capital Resources below for a detailed analysis of each of the above items, including an analysis of year-over-year fluctuations.


We incurred net losses of $49.6 million and $120.3 million for the years ended
December 31, 2021 and December 31, 2020, respectively and as of December 31,
2021, we had an accumulated deficit of $365.2 million.

Material Changes and Transactions

The acquisition of Avedro, Inc.


On November 21, 2019, we acquired Avedro, Inc. (Avedro), a hybrid ophthalmic
pharmaceutical and medical technology company focused on developing therapies
designed to treat corneal diseases and disorders and correct refractive
conditions, in a stock-for-stock transaction (Avedro Merger). Avedro developed
novel bio-activated drug formulations used in combination with proprietary
systems for the treatment of progressive keratoconus and corneal ectasia
following refractive surgery. The therapy is the first and only minimally
invasive anterior segment product offering approved by the FDA shown to halt the
progression of keratoconus.

Recent Developments

2022 U.S. reimbursement rates

On November 2, 2021, the United States (U.S.) Centers for Medicare & Medicaid
Services (CMS) published its final rules for 2022 Medicare physician fee payment
rates and 2022 Medicare facility fee payment rates for services furnished in
both the ambulatory surgery center and hospital outpatient settings (Final
Rules). These Final Rules superseded the proposed rates that were issued by CMS
in July 2021 which were much lower than the rates issued in the Final Rules.
Compared to the 2021 reimbursement rates, the Final Rules contained a new,
significantly lower physician fee related to the implantation of trabecular
bypass stents, such as our iStent family of products, in conjunction with
cataract surgery. Conversely, the facility fee schedule related to surgeries
that include implantation of trabecular bypass

                                       38

Contents

stents, such as our iStent family of products, in conjunction with cataract
surgery, slightly decreases reimbursements to an ambulatory surgery center and
increases reimbursements to a hospital. We estimate that approximately 80% of
procedures utilizing our trabecular micro-bypass technologies in the U.S. are
performed in the ambulatory surgery center setting and the remaining estimated
20% of procedures are performed in the hospital. Additionally, the Final Rules
established facility fee payment rates that were lower than anticipated for
standalone insertion of an aqueous drainage device in the ambulatory surgery
center and hospital settings, which would be the procedure that such facilities
would use with our iStent infinite product, which is not yet approved by the
FDA. These CMS reimbursement rates contained in the Final Rules took effect
January 1, 2022.

U.S. glaucoma volumes were negatively impacted during the third and fourth
quarter of 2021 as typical customer ordering patterns were disrupted and
trialing of competitive products increased in anticipation of the potential 2022
CMS physician and facility fee reimbursement rate decreases becoming effective
as originally proposed in July 2021. The physician fee reimbursement rate as
issued in the Final Rules may continue to have an adverse impact on 2022
procedural iStent family product volumes, in conjunction with cataract surgery,
as well as on our 2022 U.S. combo-cataract glaucoma revenues, gross profit, and
net income, the full extent of which is not known at this time.

Attilaps License Agreement


On September 20, 2021, we announced that we had entered into a licensing
agreement (Attillaps License Agreement) with Attillaps Holdings, Inc.
(Attillaps) under which Attillaps granted us a global exclusive license to
Attillaps' proprietary library of investigational pharmaceutical compounds that
target the eradication of Demodex mites, which are the root cause of Demodex
blepharitis and often associated with meibomian gland dysfunction and related
ophthalmic diseases. Under the Attillaps Licensing Agreement, we have the
exclusive global right to research, develop, manufacture and commercialize
products using certain acetylcholinesterase inhibitors for the treatment of
ophthalmic diseases caused by Demodex mites. We paid $5.0 million upon the
signing of the Attillaps License Agreement and will have ongoing milestone and
royalty payment obligations depending on the success of the development,
approval and commercialization of the compounds.

Settlement of a patent dispute


On September 14, 2021, we entered into a settlement agreement (Settlement
Agreement) with Ivantis, Inc. (Ivantis), pursuant to which we and Ivantis agreed
to terminate the patent infringement lawsuit we had filed against Ivantis on
April 14, 2018 in the U.S. District Court for the Central District of
California, Southern Division (the Lawsuit). In the Lawsuit, we alleged that
Ivantis' Hydrus® Microstent device infringes our U.S. Patent Nos. 6,626,858 and
9,827,143. Pursuant to the terms of the Settlement Agreement, Ivantis has made
cash payments totaling $60.0 million, $30.0 million of which was paid to us
during the year ended December 31, 2021, and $30.0 million of which was paid to
us in January 2022.

Additionally, Ivantis will make quarterly royalty payments to us in the amount
of 10% of Ivantis' Hydrus Microstent U.S. sales and any international sales
supplied out of the U.S. beginning in the fourth quarter of 2021 through April
26, 2025, subject to a per-unit minimum payment. We and Ivantis have dismissed
with prejudice all of our claims against each other in the Lawsuit, which was
scheduled for trial beginning on or around September 28, 2021, and in related
lawsuits in other forums and jurisdictions. The parties also have agreed to
mutual licenses and covenants not to sue the other party for patent infringement
relating to Ivantis' Hydrus Microstent or our micro-stent devices.

Santen License Agreement


On May 18, 2021, we announced that we entered into a new development and
commercialization license agreement with Santen Pharmaceutical Co., Ltd.
(Santen) for the PreserFlo MicroShunt, superseding the previous collaboration
and distribution agreements between the two parties. Under the new agreement, we
obtain exclusive commercialization rights for the MicroShunt in the United
States, Australia, New Zealand, Canada, Brazil, Mexico and the remainder of
Latin America. The new agreement also provides us with control over development
activities for the MicroShunt in these same territories, including clinical
development and regulatory affairs activities in the United States following a
transition period. Santen submitted a premarket approval (PMA) application to
the U.S. Food and Drug Administration (FDA) in June 2020 and discussions with
the FDA remain ongoing. We did not make any payment in connection with the
execution of the license agreement; however, should we be successful in
obtaining regulatory

                                       39

  Table of Contents

approval of the PreserFlo MicroShunt, we would be required to pay Healthn a milestone payment, followed by royalties and other potential future milestones depending on the successful commercialization of the product.

Modification of the Intratus license


On April 14, 2021, we announced that we had entered into an amended licensing
agreement with Intratus, Inc. (Intratus) under which Intratus granted us a
global exclusive license to research, develop, manufacture and commercialize
Intratus' patented, non-invasive drug delivery platform for application in the
treatment of presbyopia. The addition of presbyopia expands upon the existing
agreement between us and Intratus announced on July 22, 2019. The amendment
includes a mechanism to further expand the existing agreement to other
indications, applying the active pharmaceutical ingredients being advanced by us
in glaucoma, corneal disorders and presbyopia to new ophthalmic fields.

Factors affecting our performance


In addition to the disruption resulting from COVID-19 as discussed above, the
full effects of which are difficult to predict at this time, our operations to
date have been, and we believe our future growth will be, impacted by the
following:

the rate at which we are expanding our global sales and marketing infrastructure, and

? how quickly we can continue to build awareness of our products to

patients and doctors;

? timely approval of new products by regulatory authorities and

indications for use;

our industry is highly competitive and subject to rapid and profound change

? technological, market and product developments. Our success depends on

hand, on our ability to maintain a competitive position in the development of

new products for the treatment of chronic eye diseases;

publications of clinical results by us, our competitors and other third parties

? can have a significant influence on whether, and to what extent, our

   products are used by physicians and the procedures and treatments those
   physicians choose to administer to their patients;

physicians who use our products may not perform procedures during certain

? times of the year, due to the seasonality patterns typical of some of our

procedures, or when they are absent from their practices for various reasons;

? the coverage and reimbursement rates set by CMS and third-party payers for

procedures for using our products;

our ability to achieve commercialized products from the licensing and

? distribution agreements and other partnerships in which we have entered into and

will enter in the future; and

the impact of exchange rate fluctuations, as most of our

? international sales are denominated in the local currency of the country

where we sell our products.



Further, we have made and expect to continue to make significant investments in
our global sales force, marketing programs, research and development (R&D)
activities, clinical studies, and general and administrative infrastructure.
FDA-approved investigational device exemption (IDE) or investigational new drug
(IND) studies and new product development programs in our industry are
expensive. Our operating expenses have increased significantly following our
acquisition of Avedro, and we also have incurred additional construction costs
related to our new facility in Aliso Viejo, California (Aliso Facility).

We expect 2022 near-term revenue and performance to reflect increasing competitive momentum, the impact of reduced physician fee reimbursement rates contained in the CMS Final Rules and the continued disruption resulting from COVID-19, the full effects of which are difficult to predict at this time. this time.

Although we have been profitable during certain periods of our operating history, there can be no assurance that we will be profitable or that we will generate operating cash flow in the future.


                                       40

  Table of Contents

Components of operating results

Net sales

We currently operate in one reportable segment and net sales are generated
primarily from sales of iStent products and sales of Photrexa and other
associated drug formulations, as well as our proprietary bioactivation systems,
to customers and royalty income. Revenue is recognized when control of the
promised goods or services is transferred to the customer in an amount that
reflects the consideration to which we expect to be entitled in exchange for
those products or services.

We sell the majority of our products through a direct sales organization in the
United States. Internationally, we sell our products primarily through direct
sales subsidiaries in seventeen countries and through independent distributors
in certain countries in which we do not have a direct presence or maintain a
modest commercial presence. The primary end-user customers for our products are
surgery centers, hospitals and physician private practices.

While net sales may increase as we expand our global sales and marketing
infrastructure and continue to increase awareness of our products by expanding
our sales base and increasing our marketing efforts, historically our net sales
within a fiscal year have been impacted seasonally, as demand for U.S.
ophthalmic procedures is typically softer in the first quarter and stronger in
the fourth quarter of a given year. However, we have not experienced the same
seasonality pattern in 2021 due in part to the COVID-19 pandemic and its effect
on our commercial performance may continue into future reporting periods. We
also believe the 2022 CMS physician fee and facility fee rate decreases, which
were finalized in the fourth quarter 2021, have disrupted traditional customer
ordering patterns and have resulted in our customers' trialing of competitive
products, causing reduced U.S. Glaucoma sales volumes during our third and
fourth quarter of 2021. Additionally, for several years we had commercialized
our products in the U.S. with few or no direct competitors. Other products have
now become available in the U.S. and globally, or are in development by third
parties, that have entered or could enter the market and which may affect
adoption of or demand for our products. These other products could achieve
greater commercial acceptance or demonstrate better safety or effectiveness,
clinical results, ease of use or lower costs than our products, which could
adversely impact our net sales.

Cost of sales

Cost of sales reflects the overall costs of manufacturing our products and includes raw material costs, labor costs, manufacturing overhead and the effect of changes in the reserve balance for excess and obsolete inventory. .


We manufacture our iStent products at our current headquarters in San Clemente,
California using components manufactured by third parties. We manufacture our
KXL systems at our manufacturing facilities in Burlington, Massachusetts, and we
contract with third-party manufacturers in the U.S. and Germany to produce our
Photrexa and other associated drug formulations.

Due to the relatively low production volumes of our iStent products and our KXL
systems compared to our potential capacity for those products, a significant
portion of our per unit costs is comprised of manufacturing overhead expenses.
These expenses include quality assurance, material procurement, inventory
control, facilities, equipment and operations supervision and management.

Cost of sales includes a charge equal to a low single-digit percentage of
worldwide net sales of certain current and future products, including our iStent
products, with a required minimum annual payment of $0.5 million, which amount
became payable to the Regents of the University of California (the University)
in connection with our December 2014 agreement with the University (the UC
Agreement) related to a group of our U.S. patents (the Patent Rights). This
ongoing product payment obligation will change as patent coverage on certain
products being to lapse, and will terminate entirely on the date the last of the
Patent Rights expires, which is currently expected to be in the fourth quarter
of 2022.

The cost of sales includes the amortization of $252.2 million developed technological intangible asset recognized as part of the Avedro Merger. For each of the completed years December 31, 2021 and December 31, 2020the amortization charge was $22.1 millionand for the year ended December 31, 2019the amortization charge was $2.3


                                       41

Contents


million. Additionally, cost of sales included amortization of the fair market
value inventory adjustment recorded in connection with the Avedro Merger, which
for the years ended December 31, 2020 and December 31, 2019 was $24.7 million
and $4.0 million, respectively, and was fully amortized as of December 31, 2020.

Our future gross profit as a percentage of net sales, or gross margin, will be
impacted by numerous factors including commencement of sales of products in our
pipeline, or any other future products, which may have higher product costs. Our
gross margin will also be affected by manufacturing or supply chain
inefficiencies that we may experience as we attempt to manufacture our products
on a larger scale, manufacture new products and change our manufacturing
capacity or output. Additionally, our gross margin will continue to be affected
by royalty expenses on current or future products associated with various
licensing agreements. Other factors adversely affecting our net sales in future
periods, including the impact of the COVID-19 pandemic and any related supply
chain issues, and the impact of reductions by CMS in 2022 Medicare payment rates
for certain of our products and related services, may also impact our gross
profit margins in future periods.

Selling, general and administrative expenses


Our selling, general and administrative (SG&A) expenses primarily consist of
personnel-related expenses, including salaries, sales commissions, bonuses,
fringe benefits and stock-based compensation for our executive, financial,
marketing, sales, and administrative functions. Other significant SG&A expenses
include marketing programs; advertising; post-approval clinical studies;
conferences and congresses; travel expenses; costs associated with obtaining and
maintaining our patent portfolio; professional fees for accounting, auditing,
consulting and legal services; costs to implement our global enterprise systems;
and allocated overhead expenses.

We expect SG&A expenses to continue to grow as we increase our global sales and
marketing infrastructure and general administration infrastructure in the United
States. We also expect other nonemployee-related costs, including sales and
marketing program activities for new products, outside services and accounting
and general legal costs to increase as our overall operations grow. The timing
of these increased expenditures and their magnitude are primarily dependent on
the commercial success and sales growth of our products, as well as on the
timing of any new product launches and other potential business and operational
activities.

Research and Development

Our R&D activities primarily consist of new product development projects,
pre-clinical studies, IDE and IND studies, and other clinical trials. Our R&D
expenses primarily consist of personnel-related expenses, including salaries,
fringe benefits and stock-based compensation for our R&D employees; research
materials; supplies and services; and the costs of conducting clinical studies,
which include payments to investigational sites and investigators, clinical
research organizations, consultants, and other outside technical services and
the costs of materials, supplies and travel. We expense R&D costs as incurred.
We expect our R&D expenses to continue to increase as we initiate and advance
our development programs, including our expanding surgical, pharmaceutical and
intraocular sensor development efforts and clinical trials across glaucoma,
retinal disease and corneal health.

Completion dates and costs for our clinical development programs include seeking
regulatory approvals and our research programs vary significantly for each
current and future product candidate and are difficult to predict. As a result,
while we expect our R&D costs to continue to increase for the foreseeable
future, we cannot estimate with any degree of certainty the costs we will incur
in connection with the development of our product candidates. We anticipate we
will make determinations as to which programs and product candidates to pursue
and how much funding to direct to each program and product candidate on an
ongoing basis in response to the scientific success of early research programs,
results of ongoing and future clinical trials, as well as ongoing assessments as
to each current or future product candidate's commercial potential and our
likelihood of obtaining necessary regulatory approvals. We are not currently
able to fully track expenses by product candidate.

                                       42

Contents

Currently researching and development


Our in-process research and development (IPR&D) expenses relate to the amendment
of our exclusive licensing agreement with Intratus, Inc. and our Attillaps
License Agreement. Upfront payments of $5.0 million were made in connection with
each of these agreements and were expensed to IPR&D as management determined
there were no alternative future uses for the technology acquired.

Dispute Settlement


Pursuant to the terms of the Settlement Agreement, Ivantis paid us $30.0 million
during the year ended December 31, 2021. The $30.0 million cash payment received
during the year ended December 31, 2021 is included in litigation-related
settlement as a reduction of operating expenses on the consolidated statements
of operations.

Non-operating income (expenses), net

Non-operating (expense) income, net primarily consists of interest expense
associated with our finance lease for our Aliso Facility and for our Convertible
Notes, interest income derived from our short-term investments and unrealized
gains and losses arising from exchange rate fluctuations on transactions
denominated in a currency other than the U.S. dollar, primarily related to
intercompany loans.

Income taxes

Our tax provision is primarily comprised of state and foreign income taxes. Our
net deferred tax liability of $7.3 million at December 31, 2021 represents the
excess of our indefinite-lived deferred tax liabilities over our
indefinite-lived deferred tax assets. We continue to provide a full valuation
allowance against our other net deferred tax assets.

We record reservations for uncertain tax positions when we believe that the ability to maintain the tax position does not reach a more likely than not threshold.

Operating results


For discussion related to the results of operations and changes in financial
condition for the year ended December 31, 2020 compared to the year ended
December 31, 2019 refer to "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in Part II, Item 7 of our 2020 Annual
Report on Form 10-K, which was filed with the United States Securities and
Exchange Commission on March 1, 2021.

Comparison of completed exercises December 31, 2021 and December 31, 2020

                                                      Year ended
                                                    December 31,    % Increase
(in thousands)                               2021           2020    (decrease)
Statements of operations data:
Net sales                              $  294,011    $   224,959            31 %
Cost of sales                              66,627         91,719          (27) %
Gross profit                              227,384        133,240            71 %
Operating expenses:
Selling, general and administrative       179,257        171,401             5 %
Research and development                  100,999         85,392            18 %
In-process research and development        10,000              -           

NM

Litigation-related settlement            (30,000)              -           
NM
Total operating expenses                  260,256        256,793             1 %
Loss from operations                     (32,872)      (123,553)          (73) %
Non-operating loss, net                  (16,395)        (8,761)            87 %
Income tax provision (benefit)                326       (11,966)           
NM
Net loss                               $ (49,593)    $ (120,348)          (59) %


NM = Not Meaningful

                                       43

  Table of Contents

Net Sales

Our net sales are generated primarily from sales of iStent products to customers
and sales of Photrexa and associated drug formulations as well as KXL systems to
customers. Customers are primarily comprised of ambulatory surgery centers,
hospitals and physician private practices, with distributors being used in
certain international locations where we currently do not have a direct
commercial presence.

Net sales for the years ended December 31, 2021 and December 31, 2020 were
$294.0 million and $225.0 millionrespectively reflecting an increase in $69.0 million or 31%.


Net sales of glaucoma products in the U.S. were $170.8 million and
$133.7 million for the years ended December 31, 2021 and December 31, 2020,
respectively, increasing by approximately 28% primarily due to the demand for
combined cataract and glaucoma procedures increasing during the year ended
December 31, 2021 as compared to the year ended December 31, 2020 given a return
to more normalized procedure levels following the rollout of the COVID-19
vaccines, a trend that generally continued throughout 2021, with periodic demand
volatility in certain geographies in which we operate. We also believe the 2022
CMS physician fee and facility fee rate decreases that were proposed in July
2021 disrupted traditional customer ordering patterns and resulted in our
customers' trialing of competitive products.

International sales of glaucoma products for the years ended December 31, 2021
and December 31, 2020 were $61.2 million and $45.6 million, respectively,
increasing by approximately 34%. The increase in international sales reflects
growing demand in many key international markets for combined cataract and
glaucoma procedures during the year ended December 31, 2021 as compared to the
year ended December 31, 2020 given a return to more normalized procedure levels
following the rollout of the COVID-19 vaccines, a trend that generally continued
throughout 2021, with periodic demand volatility in certain international
geographies in which we operate, and favorable foreign exchange rates compared
to the prior year.

Net sales of corneal health products were $62.0 million and $45.6 million for
the years ended December 31, 2021 and December 31, 2020, respectively,
increasing by 36%. The $16.4 million increase in net sales generated from our
corneal health products was comprised of an increase of approximately $13.6
million in U.S. sales using direct sales operations and an increase of $2.8
million internationally where we utilize distributors given we do not have a
direct commercial presence, due to these distributors returning to their more
stabilized pre-COVID ordering patterns. The $13.6 million increase in U.S. sales
of corneal health products includes an increase of approximately $14.7 million
of Photrexa net sales, partially offset by reductions of approximately $1.1
million in U.S. capital equipment sales. Sales of corneal health products in
2020 were negatively impacted by disruption resulting from COVID-19. Demand for
corneal health products increased during the year ended December 31, 2021 given
a return to more normalized procedure levels following the rollout of the
COVID-19 vaccines, a trend that generally continued throughout 2021.
Additionally, corneal health sales for the year ended December 31, 2021 were
positively impacted by higher realized average sales and continued new account
starts.

Cost of Sales

Cost of sales for the years ended December 31, 2021 and December 31, 2020 were
$66.6 million and $91.7 million, respectively, reflecting a decrease of
approximately $25.1 million or 27%. The decrease was primarily comprised of a
decrease of approximately $24.7 million related to the acquisition fair market
value inventory adjustment rollout that was fully amortized as of December 31,
2020, and a decrease of approximately $2.3 million, net related to the
acquisition fair market value inventory adjustment recorded in 2020 in
connection with the Avedro Merger that was fully amortized as of December 31,
2020. These decreases were partially offset by normal increases in cost of sales
due to higher net sales for the year ended December 31, 2021 as compared to the
year ended December 31, 2020. Our gross margin was approximately 77% for the
year ended December 31, 2021 compared to approximately 59% for the year ended
December 31, 2020. The increased gross margin resulted primarily from the
increased net sales during the year ended December 31, 2021 as discussed above,
the aforementioned fair market value inventory adjustment and, to a lesser
extent, changes in product mix, most notably the inclusion of modestly lower
margin products related to international market sales.

                                       44

Contents

Selling, general and administrative expenses

General and administrative expenses for the years ended December 31, 2021 and December 31, 2020 were
$179.3 million and $171.4 millionrespectively reflecting an increase in
$7.9 million or 5%.

Of the total $179.3 million, approximately $102.6 million was comprised of
compensation and related employee expenses, with the remaining $76.7 million
spent on our marketing programs, advertising, post-approval clinical studies,
conferences and congresses, travel expenses, costs associated with obtaining and
maintaining our patent portfolio, and professional fees for accounting,
auditing, consulting and legal services.

We incurred approximately $112.4 million and $98.2 million in commercial
personnel and discretionary spending in the years ended December 31, 2021 and
December 31, 2020, respectively, related primarily to existing sales
infrastructure in glaucoma and corneal health. We also incurred approximately
$66.8 million and $73.1 million of general and administrative personnel and
discretionary spending for the years ended December 31, 2021 and December 31,
2020 associated with our ongoing administrative functions and amortization of
our right-of-use asset related to our long-term lease for the Aliso Facility.

The above increase in SG&A expenses for the year ended December 31, 2021 was due
to a return toward more normalized levels of spending to support increased
demand for glaucoma and keratoconus procedures in certain key geographic markets
in which we operate, relative to the year ended December 31, 2020, when we
incurred temporary reductions in compensation and related employee expenses for
our executive team, senior leadership, and many others throughout the company,
and reduced professional services expenses as part of cost-savings measures in
response to the COVID-19 pandemic. These increases in SG&A expenses during the
year ended December 31, 2021 compared to the year ended December 31, 2020 were
partially offset by approximately $5.2 million in decreased patent infringement
expenses, $6.6 million in decreased stock-based compensation associated with the
various stock option and restricted stock awards we granted in connection with
the Avedro Merger, $2.2 million in decreased sales tax reserve and a decrease of
approximately $1.5 million for costs incurred for restructuring and integration
expenses related to the Avedro Merger.

Research and development costs

R&D expenses for the years ended December 31, 2021 and December 31, 2020 were
$101.0 million and $85.4 millionrespectively reflecting an increase in
$15.6 million or 18%.


We incurred $66.6 million in core R&D expenses and $34.4 million in clinical
expenses, comprised of $50.1 million in compensation and related employee
expenses with the remaining $50.9 million spent on the continued research and
development, clinical studies, regulatory activities, quality assurance,
clinical inventory and supplies for surgical glaucoma product candidates and
pharmaceutical projects, such as a pharmaceutical therapeutic system for the
treatment of keratoconus without the removal of the epithelium (often referred
to as "epi-on"), iDose and our earlier stage programs for dry eye, presbyopia,
retina and other therapeutic investments.

Currently researching and development


IPR&D expenses for the year ended December 31, 2021 related to the amendment of
our exclusive licensing agreement with Intratus and our Attillaps License
Agreement. We paid $5.0 million upon signing of each of these agreements. There
were no IPR&D expenses during the year ended December 31, 2020.

Dispute Settlement


The $30.0 million cash payment from the Settlement Agreement received during the
year ended December 31, 2021 is included in litigation-related settlement as a
reduction of operating expenses on the consolidated statements of operations.

Non-operating income (expenses), net

We had non-operating expenses, net of $16.4 million and $8.8 million for the years ended December 31, 2021 and December 31, 2020, respectively. The increase in non-operating expenses, net, is mainly related to interest expenses


                                       45

Contents


recognized related to the Convertible Notes and to the finance lease for our
Aliso Facility, as well as recognition of unrealized foreign currency losses due
to higher intercompany loan balances denominated in, and impacted by, changes in
foreign currency exchange rates.

Provision for income tax (benefit)


Our effective tax rate for the year ended December 31, 2021 was not meaningful.
For the year ended December 31, 2021 and December 31, 2020, we recorded a
provision/(benefit) for income taxes of $0.3 million and $(12.0) million,
respectively. For the year ended December 31, 2021, our tax provision was
primarily comprised of state and foreign income taxes. For the year ended
December 31, 2020, our tax benefit resulted from the issuance of the Convertible
Notes partially offset by state and foreign income taxes.

Cash and capital resources

Our principal sources of liquidity are our existing cash, cash equivalents and
short-term investments, cash generated from operating, financing and investing
activities and proceeds from our senior convertible notes issuance. Our primary
uses of cash have been for selling and marketing activities, research and
development programs, and capital expenditures.

The following table summarizes our cash and cash equivalents, short-term investments and certain working capital data as at December 31, 2021 and
December 31, 2020 (in thousands):

                              December 31,      December 31,
                                  2021              2020
Cash and cash equivalents    $      100,708    $       96,596
Short-term investments              313,343           307,772
Accounts receivable, net             33,438            36,059
Inventory                            23,011            15,809
Accounts payable                      7,333             4,371
Accrued liabilities                  56,027            45,331
Working capital (1)                 422,766           419,740

(1) Working capital corresponds to total current assets minus the total

    liabilities


Main Sources of Liquidity

We plan to fund our operations, commitments for capital expenditures and other
short and long-term known contractual and other obligations using existing cash
and investments and, to the extent available, cash generated from commercial
operations. Our existing cash and investments include the remaining net proceeds
from the Convertible Notes issued in June 2020 (after payment for the related
capped call transactions), and the $30.0 million payment by Ivantis during the
year ended December 31, 2021, which is being used for working capital and
general corporate purposes. See above in the Material Changes and Transaction
section of Item 2, Management's Discussion and Analysis of Financial Condition
and Results of Operations.

Cash, cash equivalents, short-term investments and restricted cash

Our cash, cash equivalents and short-term investments totaled approximately
$414.1 million and our restricted cash totaled approximately $9.4 million.

Operating cash flow

For the twelve months ended December 31, 2021we had positive cash inflows of
$24.7 million from operating activities.

                                       46

  Table of Contents

Senior Convertible Notes
Our Convertible Notes may be converted at the option of the holders at the times
and under the circumstances and at the conversion rate described in Note 8 of
the notes to our consolidated financial statements included in Part II, Item 8
of this Annual Report on Form 10-K. As of December 31, 2021, none of the
conditions allowing holders of the Convertible Notes to convert had been met.
These conditions are measured each quarter. For example, if our trading price
remains above 130% of the conversion price for at least 20 trading days during
the 30 consecutive trading-day period ending on, and including, March 31, 2022,
holders of the Convertible Notes would have the right to convert their
Convertible Notes during the calendar quarter beginning April 1, 2022. Upon
conversion, we will pay or deliver, as the case may be, cash, shares of our
common stock or a combination of cash and shares of our common stock, at our
election, in the manner and subject to the terms and conditions provided in the
Indenture. Settling all or a portion of the conversion obligation in cash could
adversely affect our liquidity. In addition, even if holders of the Convertible
Notes do not elect to convert their Convertible Notes, we could be required
under applicable accounting rules to reclassify all or a portion of the
outstanding principal of the Convertible Notes as a current rather than
long-term liability, which would result in a material reduction of our net
working capital.

We may seek to obtain additional financing in the future through other debt or
equity financings. There can be no assurance that we will be able to obtain
additional financing on terms acceptable to us, or at all and although we have
been profitable for certain periods in our operating history, there can be no
assurance that we will be profitable or generate cash from operations.

Short-term liquidity requirements


Our short-term liquidity requirements primarily consist of regular operating
costs, interest payments related to our senior convertible notes, funding R&D
projects, capital expenditures for the development of our facilities and office
spaces as we continue our development of our Aliso Facility, and short-term
material cash requirements as described below. As of December 31, 2021, we had
net working capital of $422.8 million, which indicates that our current assets
are more than enough to cover our short-term liabilities.

Long-term liquidity requirements


Our long-term liquidity requirements primarily consist of interest and principal
payments related to our senior convertible notes, capital expenditures for the
development of our manufacturing facilities and office spaces, and long-term
material cash requirements as described below. As demand grows for our products,
we will continue to expand global operations to meet demand through investments
in manufacturing and operations.

Material cash needs


The following table summarizes our material cash requirements, including
commitments for capital expenditures and known contractual and other obligations
as of December 31, 2021, and the amount required to satisfy those requirements
in future periods.

                                                                                           Payments due by period
                                                         Less than                                      More than
(in thousands)                                Total         1 year      1 - 3 years      3 - 5 years      5 years
Operating and finance lease
obligations                               $ 187,037    $     3,365    $      21,904    $      17,473   $  144,295
Interest payments on Convertible
Senior Notes                                 43,485          7,906           15,813           15,813        3,953
Firm purchase commitments                    28,043         26,172            1,871                -            -
Total                                     $ 258,565    $    37,443    $      39,588    $      33,286   $  148,248


After funding the current operations of our commercial activities, the first
planned use of our cash flow from operations is to provide capital funding for
our R&D and clinical activities. In addition to investing in R&D and clinical
activities, we expect to utilize cash for various capital expenditures including
the expansion and enhancement of our

                                       47

Contents


facilities. We have made and expect to continue to make significant investments
in our global sales force, marketing programs, research and development
activities, clinical studies and general and administrative infrastructure.
FDA-approved IDE and IND studies and new product development programs in our
industry are expensive.

We believe that cash flows from operating, financing and investing activities, as well as our cash and investing balances, will be sufficient to meet ongoing operations, capital expenditures, commitments, working capital requirements and other known contractual and other obligations and to meet our liquidity needs for at least the next 12 months and the foreseeable future.

Cash flow

Our historical cash outflows have primarily been associated with cash used for
operating activities such as the expansion of our sales, marketing and R&D
activities; purchase of and growth in inventory and other working capital needs;
the acquisition of intellectual property; and expenditures related to equipment
and improvements used to increase our manufacturing capacity, to improve our
manufacturing efficiency and for overall facility expansion.

The following table is a condensed summary of our cash flows for the periods
indicated:

                                                                             Year ended
                                                                           December 31,
(in thousands)                                                      2021           2020

Net cash provided by (used in):
Operating activities                                          $   24,708    $  (22,988)
Investing activities                                            (58,232)      (205,060)
Financing activities                                              39,260        262,542
Exchange rate changes                                            (1,774)           (88)

Net increase in cash, cash equivalents and restricted cash $3,962 $34,406

AT December 31, 2021, our cash and cash equivalents were held for working capital purposes. We do not make investments for commercial or speculative purposes. Our policy is to invest any cash in excess of our immediate needs in investments designed to preserve the principal balance and provide liquidity.

Operational activities

In the year ended December 31, 2021 our operational activities provided $24.7 million and for the years ended December 31, 2020 our operational activities used
$23.0 million.


For the year ended December 31, 2021, our net cash provided by operating
activities reflected our net loss of $49.6 million, adjusted for non-cash items
of $70.7 million, primarily consisting of stock-based compensation expense of
$30.1 million, depreciation and amortization of $29.7 million, amortization of
lease right-of-use assets of $4.8 million, and amortization of debt issuance
costs of $1.4 million. This was partially offset by changes in operating assets
and liabilities of $3.6 million, which resulted from increases in accounts
payable and accrued liabilities and decreases in accounts receivable, partially
offset by increases in inventory and prepaids and other current assets.

For the year ended December 31, 2020, our net cash used in operating activities
reflected our net loss of $120.3 million, adjusted for non-cash items of $100.6
million, primarily consisting of stock-based compensation expense of
$46.5 million, depreciation and amortization of $29.4 million, amortization of
the inventory fair value adjustment as a result of the Avedro Merger of $24.7
million, amortization of lease right-of-use assets of $5.2 million, the fair
value of cash-settled stock options of $3.2 million and a deferred income tax
benefit of $12.2 million. This was offset by changes in operating assets and
liabilities of $3.2 million, which resulted from decreases in accounts
receivable, inventory, and other assets partially offset by decreases in
accounts payable and accrued liabilities and increases in prepaid expenses
and
other assets.

                                       48

  Table of Contents

Investing Activities

In the year ended December 31, 2021 and December 31, 2020 net cash flow from investing activities used approximately $58.2 million and $205.1 millionrespectively.


In the year ended December 31, 2021, we used approximately $215.3 million for
purchases of short-term investments, received proceeds from sales and maturities
of short-term investments of $206.9 million and used approximately $2.1 million
related to investments in company-owned life insurance.

In the year ended December 31, 2020, we used approximately $301.0 million for
purchases of short-term investments, received proceeds from sales and maturities
of short-term investments of $104.7 million and used approximately $1.8 million
related to investments in company-owned life insurance.

Cash used for the purchase of property, plant and equipment was approximately $47.8 million and $6.9 million for the years ended December 31, 2021 and December 31, 2020respectively.


We expect to increase our investment in property and equipment in the future as
we expand our manufacturing capacity for current and new products, improve our
manufacturing efficiency and for overall facility expansion, as discussed above.

Fundraising activities

In the past years December 31, 2021 and December 31, 2020 our fundraising activities provided $39.3 million and $262.5 million net cash, respectively.


In the year ended December 31, 2021, we received $30.9 million from the
exercises of stock options and purchases of our common stock by employees
pursuant to our Employee Stock Purchase Plan and used $3.7 million for payment
of employee taxes related to restricted stock unit vestings. Additionally, we
received $12.7 million in proceeds from our tenant improvement allowances of our
Aliso Facility and paid $0.7 million in principal on our finance lease.

In the year ended December 31, 2020, we received net cash proceeds of
approximately $287.5 million related to our Convertible Notes, used $9.6 million
for transaction costs related to the Convertible Notes and used $35.7 million on
payment of the capped call transaction related to the Convertible Notes. We
received net cash proceeds of approximately $24.2 million from the exercises of
stock options and purchases of our common stock by employees pursuant to our
Employee Stock Purchase Plan and used $3.9 million for payment of employee taxes
related to restricted stock unit vestings.

In addition to the amounts included in the table above, there may be significant cash obligations associated with our convertible notes in the event that they become convertible and are converted.

We do not have any off-balance sheet arrangements or significant interests in variable interest entities.

Significant Accounting Policies and Estimates

Management's discussion and analysis of our financial condition and results of
operations are based on our consolidated financial statements, which have been
prepared in accordance with U.S. generally accepted accounting principles
(GAAP). The preparation of these consolidated financial statements requires us
to make estimates and judgments that affect the reported amounts of assets and
liabilities and related disclosure of contingent assets and liabilities, revenue
and expenses at the date of the consolidated financial statements. Generally, we
base our estimates on historical experience and on various other assumptions in
accordance with GAAP that we believe to be reasonable under the circumstances.
Actual results may differ materially from these estimates under different
assumptions or conditions and such differences could be material to our
financial position and results of operations.

                                       49

Contents


While our significant accounting policies are more fully described below and in
the Notes to our consolidated financial statements appearing elsewhere in this
Annual Report on Form 10-K, we believe the following accounting policies to be
most critical for fully understanding and evaluating our financial condition and
results of operations.

Revenue Recognition

We derive our revenue from the sale of our products in United States and internationally. Customers are primarily made up of outpatient surgery centers, hospitals and private medical practices, with distributors used in some international locations where we do not have a direct commercial presence.

We concluded that one performance obligation exists for the majority of our
contracts with customers which is to deliver products in accordance with our
normal delivery times. Revenue is recognized when this performance obligation is
satisfied, which is the point in time when we consider control of a product to
have transferred to the customer. Revenue recognized reflects the consideration
to which we expect to be entitled in exchange for those products or services. We
have determined the transaction price to be the invoice price, net of
adjustments, which includes estimates of variable consideration for certain
product returns. We only recognize revenue when it is probable that we will
collect the consideration we are entitled to in exchange for the goods
transferred to a customer. This requires management to perform an assessment
related to the probability of collecting the consideration. The assessment can
contain judgment when it is performed for customers with declining credit
conditions or those with no history or a limited history of product sales with
us.

We offer volume-based rebate agreements to certain customers and, in these
instances, we provide a rebate (in the form of a credit memo) at the contract's
conclusion, if earned by the customer. In such cases, the transaction price is
allocated between our delivery of product and the issuance of a rebate at the
contract's conclusion for the customer to utilize on prospective purchases. The
performance obligation to issue a customer's rebate, if earned, is transferred
over time and our method of measuring progress is the output method, whereby the
progress is measured by the estimated rebate earned to date over the total
rebate estimated to be earned over the contract period. The provision for
volume-based rebates is estimated based on customers' contracted rebate programs
and the customers' projected sales levels. We periodically monitor our customer
rebate programs to ensure the rebate allowance is fairly stated. Our rebate
allowance is included in accrued liabilities in the consolidated balance sheets
and estimated rebates accrued were not material during the periods presented.

Customers are not granted specific rights of return; however, we may permit
returns of certain products from customers if such product is returned in a
timely manner and in good condition. We generally provide a warranty on our
products for one year from the date of shipment, and offer an extended warranty
for our KXL systems. Any product found to be defective or out of specification
will be replaced or serviced at no charge during the warranty period. Estimated
allowances for sales returns and warranty replacements are recorded at the time
of sale of the product and are estimated based upon the historical patterns of
product returns matched against sales, and an evaluation of specific factors
that may increase the risk of product returns. Product returns and warranty
replacements to date have been consistent with amounts reserved or accrued and
have not been significant. If actual results in the future vary from our
estimates, we will adjust these estimates which would affect net product revenue
and earnings in the period such variances become known.

Stock-based compensation expense

Stock-based compensation expense for stock options is measured at the date of
grant, based on the estimated fair value of the award using the Black-Scholes
option pricing model.

Stock-based compensation expense for restricted stock units is also measured at the date of grant, based on the closing price of our common stock.


For awards subject to time-based vesting conditions, we recognize stock-based
compensation expense over the requisite service period on a straight-line basis,
net of estimated forfeitures.

                                       50

Contents


The estimation of the fair value of each stock-based option grant or issuance on
the date of grant involves numerous assumptions by management. Although we
calculate the fair value under the Black-Scholes option pricing model, which is
a standard option pricing model, this model still requires the use of numerous
assumptions, including, among others, the expected life (turnover), volatility
of the underlying equity security, a risk free interest rate and expected
dividends. During the year ended December 31, 2021 the Company based the
expected volatility on a weighted average of the historical volatility of its
common stock and historical volatilities of a peer group of similar companies
over the most recent period commensurate with the estimated expected term of the
Company's stock options. During the years ended December 31, 2020 and 2019, the
expected volatility assumption was based on historical volatilities of a peer
group of similar companies whose share prices were publicly available. The peer
group was developed based on companies in the biotechnology industry. We have
estimated the expected term of our stock options using the "simplified" method,
whereby the expected life equals the average of the vesting term and the
original contractual term of the option. The use of different values by
management in connection with these assumptions in the Black-Scholes option
pricing model could produce substantially different results.

Recent accounting pronouncements


For a description of recent accounting pronouncements, see Note 2 of the notes
to our consolidated financial statements included in Part II, Item 8 of this
Annual Report on Form 10-K.

© Edgar Online, source Previews

]]>
5 Best Opticians in Anaheim, CA https://web-xpress.com/5-best-opticians-in-anaheim-ca/ Thu, 24 Feb 2022 15:03:44 +0000 https://web-xpress.com/5-best-opticians-in-anaheim-ca/ Below is a list of the best and leading opticians in Anaheim. To help you find the best opticians located near you in Anaheim, we’ve compiled our own list based on this rating point list. The best opticians in Anaheim: The top rated Opticians in Anaheim, CA are: Glasses optometry – provide the highest quality […]]]>

Below is a list of the best and leading opticians in Anaheim. To help you find the best opticians located near you in Anaheim, we’ve compiled our own list based on this rating point list.

The best opticians in Anaheim:

The top rated Opticians in Anaheim, CA are:

  • Glasses optometry – provide the highest quality eye care
  • Eye Vista Optometry – strive to put the interests of their patients first
  • Downtown Anaheim Family Optometry – offer a wide range of optometry services
  • Precision Vision Optometry – Anaheim – All their doctors are TMOD certified
  • Anaheim Eye Care Optometry – provide thorough eye exams

Glasses optometryOpticians in Anaheim

Glasses optometry always strives to offer the best technology and it starts before you even walk into their office. You can electronically complete any questions they need to know before your visit. They offer a wide range of services from comprehensive eye exams for patients of all ages to contact lens exams, dry eye exams, glaucoma management and medical checkups for any emergency that may occur. Their professional goal is to provide the highest quality eye care to every patient they see.

Their comprehensive exam uses state-of-the-art technology testing your eyes for proper prescription and neurological integrity, evaluating all eye diseases including glaucoma, cataracts and macular degeneration. They also strive to give back as much as they can, whether by donating eyewear, partnering with generous frame lines, or hosting school screenings and veteran exams.

Products:

Comprehensive eye exams, digital retinal assessments, contact lens evaluations, and more.

LOCATION:

Address: 5655 E La Palma Ave Suite 150, Anaheim Hills, CA 92807
Call: (714) 340-0520
Website: www.spectacleoptometry.com

COMMENTS:

“It was the first time I came here and I’m delighted! The office is absolutely adorable and spotless. Dr. Bovy did a thorough examination and explained everything to me. They have a wonderful selection of glasses, I love my new glasses! Thank you Dr Bovy, I will definitely come back.” -Susan W.

Eye Vista OptometryBest Opticians in Anaheim

Eye Vista Optometry offers a variety of vision services, ranging from comprehensive eye exams to custom eyeglasses and custom contact lens fitting. With special training in low vision rehabilitation and the use of the latest technology, Dr. Tran accurately diagnoses, treats and manages the range of medically related eye conditions such as red eye, dry eye, diabetes and low vision. They strive to put the interests of their patients first and educate them about their eye health and well-being.

Products:

Low vision rehabilitation, Glasses, Professional glasses

LOCATION:

Address: 1092 N State College Blvd, Anaheim, CA 92806
Call: (714) 635-8671
Website: www.eyevistaanaheim.com

COMMENTS:

“They have better frames than most places and have the best prices. Don’t waste time looking for prescription eyes or sunglasses, check out these guys. – Howie G.

Downtown Anaheim Family OptometryAnaheim Opticians

Downtown Anaheim Family Optometry, formerly the practice of Dr. Hershel Welton OD. Their team of professionals is dedicated to providing their patients with the highest quality optometry care. They offer a wide range of optometry services so that all of your family’s needs are met under one roof. Their goal is for you to leave their office with an unforgettable and enjoyable experience, which is why their welcoming and compassionate staff will go out of their way to make you feel at home.

Part of alleviating your concerns is explaining what you can expect from their practice. When you are new to their office, they strive to provide you with a positive and comforting experience. Once you’ve been with them for a while, you can continue to expect the highest level of service.

Products:

Comprehensive eye exams, contact lenses, glaucoma, myopia control

LOCATION:

Address: 303 W Lincoln Ave Suite #120, Anaheim, CA 92805
Call: (714) 535-8404
Website: www.anaheimfamilyoptometry.com

COMMENTS:

“Super friendly staff and great selection of frames. Dr. Shu gave me a thorough eye exam, answered all of my questions/concerns, and was very personable. There was also plenty of parking space and the office was clean. – Linda K.

Precision Vision Optometry – AnaheimGood opticians in Anaheim

Precision Vision Optometry – Anaheim is delighted to provide you with professional eye care services in a comfortable and friendly environment. Precision Vision Optometry has two full-service facilities open seven days a week. Whether it’s time for your comprehensive eye exam or you need a contact lens fitting, they’ve got you covered. All of their doctors are TMOD certified, which means they can detect and treat many eye diseases and conditions.

Their infirmaries have more than 5,000 spectacle frames and 2,000 contact lenses in stock. They have one of the largest selections of frames fully covered by VSP and other vision insurance. They offer frames of all shapes, colors, sizes, brands and prices. They love kids and have plenty of durable, affordable and fun frames for them.

Products:

One-hour service on eyeglasses and contact lenses, free consultations on laser vision correction, and more.

LOCATION:

Address: 661 N Euclid St, Anaheim, CA 92801
Call: (714) 817-0606
Website: www.precisionvisionoptometry.com

COMMENTS:

“The staff are excellent and they don’t try to sell you. They work with your insurance and your budget. I can’t believe a reviewer gave me 1 star because she’s been going there for years. Everyone is having a bad day. I can say this place is not perfect but they are professional.” – Michelle R.

Anaheim Eye Care OptometryOne of the best opticians in Anaheim

Anaheim Eye Care Optometry, their mission is to give comprehensive eye assessments in a family setting, with an emphasis on excellent customer service. They strive to provide thorough eye exams focused on preventing eye disease and educating their patients about healthy eye care. They provide extraordinary eyewear to fit any active lifestyle. They are also subgenres in medical optometry such as red eye, ocular diabetes, glaucoma, cataracts, and hard-to-fit contacts.

They strive to educate people on the importance of annual checkups to prevent and control eye disease. Anaheim Eye Care Optometry provides community outreach by meeting with local leaders, attending health fairs, participating in religious events, administering school screenings, and working alongside other physicians to promote eye care.

Products:

Comprehensive eye exam, contact lens fitting and follow-up, dilated fundus examination, eyeglass fitting

LOCATION:

Address: 947 S Anaheim Blvd #230, Anaheim, CA 92805
Call: (714) 491-0881
Website: www.anaheimeyecare.net

COMMENTS:

“I went for a contact lens fitting and it was a great experience with Dr. Vargas. I am happy with the results. – Edward B.

]]>
Light-based treatment could be key to dry eye management – NBC 5 Dallas-Fort Worth https://web-xpress.com/light-based-treatment-could-be-key-to-dry-eye-management-nbc-5-dallas-fort-worth/ Tue, 22 Feb 2022 03:46:56 +0000 https://web-xpress.com/light-based-treatment-could-be-key-to-dry-eye-management-nbc-5-dallas-fort-worth/ About 16 million adults live with dry eye disease in the United States. It is a condition that occurs when your tears are unable to produce adequate lubrication for your eyes, which dries them out and causes an itchy or burning sensation. Over-the-counter drops may provide temporary relief, but a treatment originally used to treat […]]]>

About 16 million adults live with dry eye disease in the United States. It is a condition that occurs when your tears are unable to produce adequate lubrication for your eyes, which dries them out and causes an itchy or burning sensation. Over-the-counter drops may provide temporary relief, but a treatment originally used to treat rosacea, a skin condition, provides patients with long-lasting relief.

Whether it’s acting, playing guitar, or flying, Phyllis Spielman is always up for a new challenge, but battling dry eye wasn’t a challenge she expected.

“The worst thing you can have is itchy and burning eyes because it’s a distraction. You could cause an accident,” Spielman explained.

When over-the-counter drops and squeezes didn’t work the way Spielman hoped, she turned to her doctor for help.

“You give someone artificial tears and say, ‘Just lubricate your eye and you’ll be fine,’ but this is an inflammatory disease,” said Dr. Rolando Toyos, founder and CEO of Toyos Clinic.

Inflammation of the eye Meibomian glands is the cause of insufficient tear production. Dr. Toyos suggested the OptiLight treatment, which is a light-based treatment given in four sessions two to four weeks apart.

Patients can start feeling relief right away, and for Spielman, the treatment was a win in his book.

“It was really painless. It was quick. There was no downtime. You wouldn’t even know I had the treatment,” Spielman said.

Toyos said it is the first and only FDA-approved light treatment for dry eye management. After the first four sessions, a person with severe dry eye may need additional treatments. Dr. Toyos also said that right after a session, patients should avoid sun exposure as the skin around their eyes will be more susceptible to sunburn.

Contributors to this report include: Milvionne Chery, producer; Roque Correa, videographer, editor.

]]>
Dompé announces the enrollment of the first patient in the phase 3 trial of cenegermin in patients with severe dry eye disease related to Sjögren’s disease https://web-xpress.com/dompe-announces-the-enrollment-of-the-first-patient-in-the-phase-3-trial-of-cenegermin-in-patients-with-severe-dry-eye-disease-related-to-sjogrens-disease/ Wed, 09 Feb 2022 18:29:00 +0000 https://web-xpress.com/dompe-announces-the-enrollment-of-the-first-patient-in-the-phase-3-trial-of-cenegermin-in-patients-with-severe-dry-eye-disease-related-to-sjogrens-disease/ – Two multicenter Phase 3 clinical trials will evaluate the safety and efficacy of cenegermin in patients with severe dry eye disease related to Sjögren’s disease – The Eye Research Foundation in Newport Beach, California is one of more than 10 clinical trial sites in the United States and Europe – Dompé partners with the […]]]>

– Two multicenter Phase 3 clinical trials will evaluate the safety and efficacy of cenegermin in patients with severe dry eye disease related to Sjögren’s disease

– The Eye Research Foundation in Newport Beach, California is one of more than 10 clinical trial sites in the United States and Europe

– Dompé partners with the Sjögren Foundation to improve understanding of the disease and provide information on opportunities to participate in clinical research.

Milan, Italy and SAN MATEO, California, February 9, 2022 /PRNewswire/ — Dompé farmaceutici SpA and Dompé US Inc. (collectively Dompé) announced today that the first patient has been enrolled in its Phase 3 clinical trial to evaluate the efficacy and safety of cenegermine in patients with severe Sjögren’s dry eye, a primary symptom of Sjögren’s disease, which is often underdiagnosed1. This trial is part of a program that includes two randomized, double-blind, vehicle-controlled studies that will be conducted at more than 10 sites in the United States and Europe, 2.3 and was initiated following encouraging data from a phase 2 study, the results of which will be shared at an upcoming medical meeting. This study evaluated the efficacy and safety of cenegermin ophthalmic solution versus vehicle in patients with moderate to severe dry eye disease, including a subset of patients diagnosed with Sjögren’s disease without associated rheumatic disease. . 8

(PRNewsfoto/Dompé Farmaceutici SpA)

Sjögren’s disease (pronounced SHOW-grins) is an autoimmune disease that can affect many parts of the body. In patients who are affected, the body’s white blood cells attack certain glands, including those that provide lubrication to our eyes and mouth. Therefore, dry eye is common in people living with Sjögren’s disease.1. Dry eyes associated with Sjögren’s disease can lead to vision problems including light sensitivity, blurred vision and corneal damage4.

“The majority of Sjögren’s patients live with dry eye, and many of these patients will experience eye symptoms which can often be quite severe,” said Jeannet church, CEO of the Sjögren Foundation. “We are grateful for Dompé’s commitment to research that may lead to new treatment options for people with Sjögren’s disease who suffer from dry eye disease and we encourage people to speak to their doctor to learn more. on participation in clinical trials.

There are currently no FDA-approved treatments for Sjögren’s severe dry eye disease; it is managed by replacing moisture at the affected glandular sites and suppressing the autoimmune response locally as well as systemically1.

“With cenegermin, Dompé has led the way, leveraging decades of research to better understand how nerve growth factor (NGF) contributes to overall eye health.” noted Melissa Toyos, MD, Principal Investigator and Partner and Director of Research at Toyos Clinic. “Studies have demonstrated a neurosensory component in certain types of dry eye, suggesting that cenegermin could be an innovative option for these patients.” 9

The NGF0121 study (NCT 05133180) will enroll 100 patients and will use the Schirmer test and Symptom Assessment Questionnaire in Dry Eye (SANDE) as primary endpoints to measure improvement in signs and symptoms of dry eye over time.2. The NGF0221 study (NCT 05136170) will enroll 48 patients who are currently being treated for severe Sjögren-related dry eye with cyclosporine A3 and will use Schirmer’s test as the sole primary endpoint3. Patients in both studies will be randomized (1:1) to receive either cenegermin ophthalmic solution 20 mcg/mL or vehicle three times daily. 2.3.

“These studies illustrate our commitment to exploring how NGF science can innovate for eye diseases with unmet medical need.” noted Ashley KlinGlobal Head of Biotechnology, Dompé Farmaceutici SpA and Managing Director, Dompé US Inc. lasting effect impact on ocular tissue and help restore the natural homeostasis of the eye.” ten

For more information or a list of sites for ongoing clinical trials evaluating the safety and efficacy of cenegermin in patients with severe Sjögren’s dry eye, contact usmedinfo@dompe.com or visit www.clinicaltrials .gov.

About Oxervate® (cenegermin-bkbj ophthalmic solution)

Oxervate is a 0.002% cenegermin-bkbj (20 mcg/mL) topical solution currently approved by the FDA for the rare disease neurotrophic keratitis (NK). Its active ingredient cenegermin-bkbj, is a recombinant form of human nerve growth factor and is structurally identical to the NGF protein made naturally by the body5, 6. Nerve growth factor (NGF) is involved in the differentiation and maintenance of neurons which acts through specific high and low affinity receptors in the anterior segment of the eye to support the innervation and integrity of the cornea.seven

Oxervate is not yet FDA approved for the treatment of severe dry eye disease related to Sjögren’s disease. More information about Oxervate for Neurotrophic Keratitis can be found in the full product prescribing information: www.oxervate.com

Important Safety Information

Contact lenses should be removed prior to application of OXERVATE as the presence of a contact lens (therapeutic or corrective) could theoretically limit the delivery of cenegermin-bkbj to the area of ​​corneal injury. The lenses can be reinserted 15 minutes after administration.

OXERVATE may cause mild to moderate eye discomfort such as eye pain during treatment. The patient should be advised to contact their physician in the event of a more serious eye reaction.

The most common adverse reaction in clinical trials that occurred more frequently with OXERVATE was eye pain (16% of patients). Adverse effects included corneal deposits, foreign body sensations in the eye, ocular hyperemia (enlargement of blood vessels in the whites of the eyes), swelling (inflammation) of the eye, and increased tearing (1 in 10% of patients). seven

Domped in Ophthalmology

Dompé farmaceutici SpA is a rapidly growing privately-held global biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of medical innovation. For more than a decade, Dompé has been a leader in the research and development of innovative therapies based on neurotrophins, proteins derived from the Nerve Growth Factor (NGF). The company’s expertise in NGF began in ophthalmology and led to a breakthrough designation following FDA approval of Oxervate® for the rare disease, neurotrophic keratitis (NK). Ongoing research in ophthalmology includes post-marketing research on NK, studies on Sjögren’s severe dry eye, and other undisclosed programs. Dompé’s R&D is anchored in EXSCALATE, an in-house developed framework-based virtual scouting platform that leverages one of the world’s most powerful supercomputing and artificial intelligence platforms. Dompé employs more than 800 employees worldwide and maintains a business operations center in the United States in the San Francisco Bay Area as well as an R&D presence in Boston.

Forward-looking statements

This press release refers to certain information that may not coincide with expected future results. Dompé firmly believes in the soundness and reasonableness of the concepts expressed. However, certain information is subject to a certain degree of indeterminacy in relation to its research and development activities and the necessary checks to be carried out by regulatory bodies. Consequently, to date, Dompé cannot guarantee that the expected results will be consistent with the information provided above.

The references

1. Carsons SE, Patel BC. Sjogren’s syndrome. [Updated 2021 Aug 9]. In: StatPearls [Internet]. treasure island (FL): StatPearls Publishing; 2021 Jan-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK431049/.

2. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (USA). Identifier NCT05133180, Study to Evaluate the Safety and Efficacy of Oxervate® Ophthalmic Solution versus Vehicle in Sjögren’s Severe Dry Eye Disease (NGF0121); Updated on January 18, 2022 [accessed 2022 Jan 26]; [about 10 screens]. Available at: https://clinicaltrials.gov/ct2/show/NCT05133180?term=rhNGF&cond=dry+eye&draw=2&rank=5

3. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (USA). Identifier NCT05136170, study to evaluate the safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL versus vehicle, in patients with Sjögren’s dry eye disease (NGF0221); Updated on January 18, 2022 [accessed 2022 Jan 26]; [about 10 screens]. Available at: https://clinicaltrials.gov/ct2/show/NCT05136170?term=rhNGF&cond=dry+eye&draw=2&rank=4

4. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjögren’s syndrome. Arch Med Intern. 2004 Jun 28;164(12):1275-84. doi: 10.1001/archite.164.12.1275. PMID: 15226160.

5. Dompé Farmaceutici SpA (October 2019). OXERVATE™ (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL): Prescribing Information Highlights. Retrieved from https://oxervate.com/wp-content/uploads/2020/05/OXERVATE_Prescribe_Information_102019.pdf [Accessed 2022 Jan 26]

6. Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 1998;338:1174-80.

7. OXERVATE.com. 2019. Important Safety Information – OXERVATE™ (cenegermin-bkbj) ophthalmic solution 0.002% (20 mcg/mL) HPC. [online] Available on : [Accessed 2022 Jan 26].

8. Archived Data. NGF0118

9. Villani E, Galimberti D, Viola F, Mapelli C, Ratiglia R. The cornea in Sjogren’s syndrome: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2007 May;48(5):2017-22. doi: 10.1167/iovs.06-1129. PMID: 17460255.

10. Zhang X, M VJ, Qu Y et al. Managing dry eye: targeting the ocular surface microenvironment. Int J Mol Sci. 2017;18(7):1398. Published June 29, 2017. doi:10.3390/ijms18071398

Logo – https://mma.prnewswire.com/media/1743475/Dompe_Farmaceutici_Logo.jpg

Quote

Quote

See original content to download multimedia: https://www.prnewswire.com/news-releases/dompe-announces-first-patient-enrolled-in-phase-3-trial-of-cenegermin-in-patients-with -severe-sjogrens-related-dry-eye-disease-301479020.html

SOURCE Dompé Farmaceutici SpA

]]>